Domov › Akútna myeloidná leukémia › North Carolina
Klinické štúdie Akútna myeloidná leukémia v štáte North Carolina
43 štúdií pre Akútna myeloidná leukémia hľadá účastníkov v zariadeniach v štáte North Carolina.
Mestá v štáte North Carolina
Oficiálny text štúdie (anglicky)
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- AdventHealth Infusion Center Asheville, Asheville
- Southeastern Medical Oncology Center-Clinton, Clinton
- AdventHealth Infusion Center Haywood, Clyde
- a 6 ďalších
Prebieha náborObservačná štúdiaVítaní zdravých dobrovoľníkov
Vek 40 až 75 · Všetky pohlavia · Aktualizované 2. 10. 2026 · NCT05334069Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
- Wake Forest University Health Sciences, Winston-Salem
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 1. 10. 2026 · NCT06484062Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- Carolinas Medical Center/Levine Cancer Institute, Charlotte
- Novant Health Presbyterian Medical Center, Charlotte
- Duke University Medical Center, Durham
- a 3 ďalších
Prebieha náborFáza 2
Vek 18 až 59 · Všetky pohlavia · Aktualizované 28. 9. 2026 · NCT05554393A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
- Atrium Health, Charlotte
- Novant Health Charlotte, Charlotte
- Carolina Oncology Specialists, Charlotte
- a 2 ďalších
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 25. 9. 2026 · NCT06852222MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
- Carolinas Medical Center/Levine Cancer Institute, Charlotte
- Novant Health Presbyterian Medical Center, Charlotte
- a 5 ďalších
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 25. 9. 2026 · NCT05564390Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
- Carolinas Medical Center/Levine Cancer Institute, Charlotte
- Duke University Medical Center, Durham
- East Carolina University, Greenville
- a 1 ďalších
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 22. 9. 2026 · NCT06317649Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
- Carolinas Medical Center/Levine Cancer Institute, Charlotte
- Duke University Medical Center, Durham
- East Carolina University, Greenville
- a 1 ďalších
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 22. 9. 2026 · NCT06672146Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
- Carolinas Medical Center/Levine Cancer Institute, Charlotte
- Duke University Medical Center, Durham
- East Carolina University, Greenville
- a 1 ďalších
Prebieha náborFáza 2
Vek 18 až 59 · Všetky pohlavia · Aktualizované 22. 9. 2026 · NCT05554406A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
- Mission Hospital, Asheville
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
- Carolinas Medical Center/Levine Cancer Institute, Charlotte
- a 4 ďalších
Prebieha náborFáza 3
6 Months – 21 Years · Všetky pohlavia · Aktualizované 17. 9. 2026 · NCT04293562A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
- Duke University Medical Center, Durham
Prebieha náborFáza 1/2
30 Days · Všetky pohlavia · Aktualizované 16. 9. 2026 · NCT04065399Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
- Novant Health Clinical Research, Charlotte
- East Carolina University, Greenville
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 16. 9. 2026 · NCT06824168Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS
- University of North Carolina at Chapel Hill, Chapel Hill
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 14. 9. 2026 · NCT06846606Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
- UNC School of Medicine, Division of Hematology, Chapel Hill
Prebieha náborFáza 1/2
Vek 12 a viac · Všetky pohlavia · Aktualizované 3. 9. 2026 · NCT04588922A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies
- Novant Health Weisiger Cancer Institute, Charlotte
Prebieha náborObservačná štúdia
Vek 0 a viac · Všetky pohlavia · Aktualizované 2. 9. 2026 · NCT07154823Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax
- Atrium Health Wake Forest Baptist Medical Center, Winston-Salem
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 2. 9. 2026 · NCT07471841Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
- US-Chapel Hill-UNCNORTHCAROLINA, Chapel Hill
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 2. 9. 2026 · NCT06652438A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
- Carolinas Medical Center/Levine Cancer Institute, Charlotte
- Wake Forest University Health Sciences, Winston-Salem
Prebieha náborFáza 1
Vek 18 až 75 · Všetky pohlavia · Aktualizované 25. 8. 2026 · NCT05886049The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Mission Hospital, Asheville
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
- Carolinas Medical Center/Levine Cancer Institute, Charlotte
- a 4 ďalších
Prebieha náborFáza 1/2
Do veku 22 · Všetky pohlavia · Aktualizované 25. 8. 2026 · NCT04726241Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
- University of North Carolina, Chapel Hill, Chapel Hill
- Duke University Medical Center, Durham
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 20. 8. 2026 · NCT07007312Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Atrium Health Levine Cancer Center, Charlotte
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 20. 8. 2026 · NCT06001788ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
- University of North Carolina at Chapel Hill, Chapel Hill
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 18. 8. 2026 · NCT06656494Toxicity Genetic Determinants and Response to Azacitidine and Venetoclax in AML
- Levine Cancer Institute, Charlotte
- Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
Prebieha náborObservačná štúdia
Vek 18 a viac · Všetky pohlavia · Aktualizované 24. 7. 2026 · NCT06580106ONC-LEUK-2406: The Impact of Systematic Financial Navigation in Acute Myeloid Leukemia
- Levine Cancer Insitute, Charlotte
- Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
Prebieha nábor
Vek 18 až 64 · Všetky pohlavia · Aktualizované 23. 7. 2026 · NCT06945042Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
- Research Site, Chapel Hill
- Research Site, Durham
Prebieha náborFáza 1/2
Vek 16 a viac · Všetky pohlavia · Aktualizované 20. 7. 2026 · NCT07155226Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents
- University of North Carolina at Chapel Hill, Chapel Hill
- Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 10. 7. 2026 · NCT05442216A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- University of North Carolina at Chapel Hill, Chapel Hill
- Levine Children's Hospital, Charlotte
- Duke University Medical Center, Durham
Prebieha náborObservačná štúdia
Všetky vekové kategórie · Všetky pohlavia · Aktualizované 6. 7. 2026 · NCT01351545A Decisional Intervention for Older Adults With Acute Myeloid Leukemia and Their Caregivers
- University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill
- Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Section of Hematology/Oncology, Winston-Salem
Prebieha nábor
Vek 60 a viac · Všetky pohlavia · Aktualizované 6. 7. 2026 · NCT06697600Registry of Older Patients With Cancer
- Seby B. Jones Cancer Center, Boone
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill
- East Carolina University, Greenville
- a 4 ďalších
Prebieha náborObservačná štúdia
Vek 65 a viac · Všetky pohlavia · Aktualizované 29. 6. 2026 · NCT01137825IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)
- UNC Hospitals, University of North Carolina at Chapel Hill, Chapel Hill
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 23. 6. 2026 · NCT05401097A Study of Revumenib and Mezigdomide in People With Leukemia
- University of North Carolina (Data Collection Only), Chapel Hill
Prebieha náborFáza 1/2
Vek 12 a viac · Všetky pohlavia · Aktualizované 22. 6. 2026 · NCT07356154SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation
- UNC Hospitals, University of North Carolina at Chapel Hill, Chapel Hill
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 14. 5. 2026 · NCT06222580Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
- University of North Carolina, Chapel Hill
Prebieha náborFáza 1
Vek 13 a viac · Všetky pohlavia · Aktualizované 5. 5. 2026 · NCT04771572A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- Duke University, Durham
Prebieha náborFáza 2/3
Vek 18 a viac · Všetky pohlavia · Aktualizované 30. 4. 2026 · NCT04256317The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen
- Wake Forest Baptist Health, Winston-Salem
Prebieha náborObservačná štúdia
Vek 18 až 120 · Všetky pohlavia · Aktualizované 13. 4. 2026 · NCT01890486A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- UNC Hospital, Chapel Hill
- Duke University, Durham
- Atrium Wake Forest Baptist Medical Center, Winston-Salem
Prebieha náborFáza 1/2
Vek 12 a viac · Všetky pohlavia · Aktualizované 24. 3. 2026 · NCT04988555A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
- University of North Carolina, Chapel Hill
Prebieha náborFáza 2
Vek 18 až 66 · Všetky pohlavia · Aktualizované 17. 3. 2026 · NCT06859424A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
- Duke Blood Cancer Center, Durham
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 13. 3. 2026 · NCT05735184CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
- Duke Cancer Center, Durham
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 16. 1. 2026 · NCT05143996Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS
- Novant Health Cancer Institute, Charlotte
- Novant Health Cancer Institute, Winston-Salem
Prebieha náborFáza 1/2
Vek 18 a viac · Všetky pohlavia · Aktualizované 10. 12. 2025 · NCT06680752Novel Digital Application for Patients With Acute Leukemia
- Duke University, Durham
Prebieha nábor
Vek 18 až 120 · Všetky pohlavia · Aktualizované 10. 11. 2025 · NCT06472128Z ClinicalTrials.gov, dáta načítané 5. 10. 2026. Každá štúdia má vlastné kritériá oprávnenosti; tím štúdie rozhoduje o účasti.